Envista Holdings (NVST) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.41
- Estimate
- $0.34
- Surprise
- +22.1%
- Revenue (period 2026-07-03)
- $730.5M
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Envista Holdings (NVST) beat the $0.34 estimate with diluted EPS of $0.41 — a large 22.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVST Hold at 6.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +22.1% surprise compares with a +17.7% four-quarter average. Next scheduled report: 2026-10-28.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Geographic: North America (51.0%)
- Concentration risk — Supplier: sole or limited source suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.59
- Price target
- $28.42
- Stop
- $25.93
- Upside to target
- +3.0%
The stock trades at 47.6× trailing but 16.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
NVST at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $4.43B
- P/E (fwd)
- 16.5
- P/E (ttm)
- 47.6
- 52-week range
- $18.77–$30.42
- Off 52-week high
- 9.3%
- RSI (14)
- 45
- Volume vs avg
- 1.00×
- Score today
- 6.1/10